Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | WNT1 | P04628 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25263906 | 0.86 | ALDH1A1 (0.61) | CNR1MAPK1ALDH1A1NPC1MAPT | |
| SCHEMBL25348252 | 0.84 | CNR1 (0.43) | CNR1MAPK1ALDH1A1NPC1MAPT | |
| SCHEMBL30520246 | 0.84 | CNR1 (0.43) | CNR1MAPK1ALDH1A1NPC1MAPT | |
| SCHEMBL25255621 | 0.84 | USP30 (0.43) | CNR1MAPK1ALDH1A1NPC1MAPT | |
| SCHEMBL25222092 | 0.83 | SMN1; SMN2 (0.46) | ALDH1A1MAPTHTTWNT1GSK3B | |
| SCHEMBL30429285 | 0.78 | PGK1 (0.42) | WNT1GSK3BDYRK1A | |
| SCHEMBL25268453 | 0.78 | PGK1 (0.42) | WNT1GSK3BDYRK1A | |
| SCHEMBL25347731 | 0.74 | SMARCA2 (0.50) | CNR1MAPK1ALDH1A1NPC1MAPT | |
| SCHEMBL30520235 | 0.74 | SMARCA2 (0.50) | CNR1MAPK1ALDH1A1NPC1MAPT | |
| SCHEMBL25224981 | 0.70 | MAPT (0.52) | ALDH1A1MAPTHTTUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570650-B2 | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders | AURIGENE ONCOLOGY LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| US-20240018134-A1 | 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2024-01-18 | — | — | US | disclosed |
| US-20240018134-A1 | 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2024-01-18 | — | — | US | disclosed |
| US-20240018134-A1 | 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2024-01-18 | — | — | US | disclosed |
| CN-116529250-A | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degrading agents | 奥里吉恩肿瘤学有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-4192835-A1 | 6-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | Aurigene Oncology Limited (IN) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018134-A1 | 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders | SMARCC1, SMARCC2, SMARCA4 | CNR1 3411/4885MAPK1 2011/4885ALDH1A1 1495/4885 |
| US-12570650-B2 | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders | SMARCC1, SMARCC2, SMARCA1 | CNR1 1936/4885MAPK1 3697/4885ALDH1A1 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.